Grey Wolf Therapeutics secures funding for cancer therapies development21 Jan 2020
The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.
Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for immuno-oncology (IO), has completed a £2.5 million ($3.3 million) Series A2 financing round with international healthcare investors Andera Partners and Canaan.
The new funding will allow the company to accelerate development of therapies targeting endoplasmic reticulum aminopeptidase 2 (ERAP2), following many positive signals of its potential. Funds will also be used to continue to drive the lead endoplasmic reticulum aminopeptidase 1 (ERAP1) modulator program.
For context, both of Grey Wolf’s novel ERAP approaches are aimed at directly altering tumour cells, illuminating them for attack and destruction by the immune system. The goal is to exploit this increased tumour visibility in monotherapy and to extend the therapeutic benefit of already approved immunotherapies to many more cancers. The company is developing small molecule modulators of ERAP1 and ERAP2, two key proteins in the antigen presentation pathway, to change the antigen repertoire of tumours and thereby increase the number and range of cancer-related antigens, including neoantigens, presented on tumor cells available to engage an immune response.
“We are delighted to have the continued support of Andera and Canaan.” said Peter Joyce, CEO and Co-Founder. “The financing reflects growing potential in both our ERAP1 and ERAP2 approaches. We continue to see momentum, both in our own work and in the broader scientific community. These funds will allow us to further capitalize on this opportunity and expand our leadership position in the discovery and development of both ERAP1 and ERAP2 modulators.”
Grey Wolf is expanding efforts around ERAP2 for two reasons. First, clinical data continue to demonstrate that tumours that are more visible to the immune system show improved responses to checkpoint inhibitors. One such example is the recent November 2019 paper published in Nature Medicine by the Chan group at MSKCC. The results are consistent across patients that have either a higher tumour mutational burden, heterozygosity of the Class I HLA locus or greater structural/sequence divergence at the Class I HLA locus. Second, the company has developed unique insight into the targeting of the ERAP enzymes through the lead program ERAP1 and validated the role for ERAP inhibition in modulating the cancer-related antigen repertoire. These in-house data provide compelling evidence that the therapies could have a real impact on the treatment of oncology.
“We have continued to generate data showing that modulation of both ERAP pathways drives change to the cancer-related antigen repertoire,” said Tom McCarthy, Executive Chairman and Co-Founder of Grey Wolf Therapeutics. “Data clearly demonstrate that modulation of ERAP2 drives an altogether different change to the antigen repertoire when compared with ERAP1 modulation, due to ERAP2’s clearly differentiated peptide substrate specificities. With this investment and the prior knowledge base within Grey Wolf, we will be able to accelerate the ERAP2 program quickly through optimization, building on our leading position in ERAP disease-related biology.”
The additional funds represent further confidence from investors. “Grey Wolf has already provided compelling insight into the potential of ERAP1 modulation,” said Raphaël Wisniewski, Partner at Andera Partners. “This timely investment further underlines our excitement in these approaches. Grey Wolf is fast becoming true experts in modulation of ERAP biology for treatment of cancer.”
Brent Ahrens, General Partner at Canaan, added: “Canaan continues to be excited by the potential of targeting the ERAP pathway and are impressed with the progress the team has made in such a short space of time since closing Series A. The additional A2 investment enables the Company to push forward ERAP2 whilst maintaining the momentum on the lead ERAP1 program.”
Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD
21 Feb 2020
Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.Read more
Catalent to manufacture first-in-class mAb targeting solid tumours
11 Feb 2020
ZM008 could have potential benefits for the treatment of prostate cancer.Read more
BD completes clinical trial for its wearable injector
11 Feb 2020
The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.Read more
New Velesco Pharma clinical manufacturing facility begins operations
5 Feb 2020
The facility will triple the company’s cGMP clinical trial manufacturing capacity.Read more
Inovio and Beijing Advaccine to advance vaccine against Coronavirus
30 Jan 2020
Agreement will facilitate clinical trial translations in China.Read more
First human trial of monoclonal antibody to prevent malaria opens
28 Jan 2020
If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.Read more
Thermo launches next-generation, compressor-free plate sealer
28 Jan 2020
Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.Read more
Merck invests in biotech development facility in Switzerland
27 Jan 2020
€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.Read more
Diabetes diagnosis - now a matter of sweat and tears?
21 Jan 2020
No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.Read more
BioMarin gets go-ahead to start gene therapy clinical trials
15 Jan 2020
BMN 307 represents a potential third PKU treatment option from BioMarin and its second gene therapy clinical program.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation